热切期待针对这一脆弱但多样化的人群开展的临床试验,以及纳入老年评估和患者报告的结局,将为老年DLBCL复发患者提供更明确的治疗方案。 参考文献 Wallace DS,et al.How I Treat Older Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma.Blood . 2024 Oct 2:blood.2024024788. doi: 10.1182/blood.20240...
Wilson WH, Gerecitano JF, Goy A, et al, The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the ABC subtype of relapsed/refractory de novo diffuse large B-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. ...
What Kinds of Lymphoma Does Columvi Treat? Columbia treats certain types of DLBCL or LBCL that have come back after previous therapy (relapsed) or did not go away after previous therapy (refractory). How Will I Get Columvi? Columvi is injected into a vein as an intravenous (IV) infusion...
Overall, we favor ISRT for localized disease based on its low toxicity and probable PFS benefit. In the modern era, we treat most localized cases with definitive intent with 24 Gy in 12 fractions based on the noninferior outcomes from the BNLI RT dose de-escalation study [29]. Outcomes o...
Allo-HSCT from an HLA- therapy and in chemosensitive relapse of DLBCL identical sibling or MUD is a treatment option for (diffuse large B-cell lymphoma), while in young patients previously treated with relapsed patients, allo-HSCT should be consid- fludarabine-containing regimens and ...
In relapsed AML allogeneic HSCT offers the best chance of cure, ideally after the achievement of second CR (Algeri et al. 2021). Allogeneic HSCT is indicated in several dif- ferent types of lymphomas such as diffuse large B cell lymphoma (DLBCL) with relapse after autologous HSCT or in ...